Esperovax, Inc.
Esperovax is a biotechnology company based in Plymouth, MI, dedicated to developing innovative oral mRNA vaccines and therapeutics. Their proprietary platform enables the large-scale production and distribution of shelf-stable vaccines at a fraction of the cost of current injection-based treatments. They aim to become a global leader in targeted oral tablet and capsule vaccinations for many of the world's deadliest treatable diseases, providing rapid, painless, and inexpensive biological medicines to improve global health.
Industries
Nr. of Employees
small (1-50)
Esperovax, Inc.
Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, MI 48170, US
Products
Oral yeast-based RNA vaccine and biologics platform
A platform that uses engineered yeast to produce and deliver RNA or protein antigens via in-host particle production or secretion for oral administration in encapsulated dosage forms.
Preclinical oral RNA vaccine candidates
Preclinical-stage vaccine candidates developed using the yeast-based RNA/particle platform for infectious disease and biodefense indications, including influenza and SARS-CoV-2 programs.
Oral yeast-based RNA vaccine and biologics platform
A platform that uses engineered yeast to produce and deliver RNA or protein antigens via in-host particle production or secretion for oral administration in encapsulated dosage forms.
Preclinical oral RNA vaccine candidates
Preclinical-stage vaccine candidates developed using the yeast-based RNA/particle platform for infectious disease and biodefense indications, including influenza and SARS-CoV-2 programs.
Services
Design and execution of preclinical immunogenicity and challenge studies for orally delivered RNA vaccine candidates.
Licensing agreements and collaboration to integrate yeast‑based manufacturing methods and continuous purification approaches with academic and commercial partners.
Collaborative development of room‑temperature stable formulations and RNA stabilization approaches for oral biologics to reduce cold‑chain dependency.
Development and optimization of yeast cell‑wall modifications and secretion phenotypes to support sustained release of RNA or antigen payloads in the gastrointestinal environment.
Design and execution of preclinical immunogenicity and challenge studies for orally delivered RNA vaccine candidates.
Licensing agreements and collaboration to integrate yeast‑based manufacturing methods and continuous purification approaches with academic and commercial partners.
Collaborative development of room‑temperature stable formulations and RNA stabilization approaches for oral biologics to reduce cold‑chain dependency.
Development and optimization of yeast cell‑wall modifications and secretion phenotypes to support sustained release of RNA or antigen payloads in the gastrointestinal environment.
Expertise Areas
- Oral vaccine development
- RNA therapeutics (mRNA, self-amplifying RNA, circular RNA)
- Yeast-based biomanufacturing and host engineering
- Thermostable formulation development and RNA stabilization
Key Technologies
- Yeast genetic engineering and secretion systems
- Enveloped virus‑like particle production
- mRNA
- Self-amplifying RNA
News & Updates
Esperovax was awarded a subcontract valued at $1.5 million for the pre-clinical development of an oral H5N1 influenza RNA vaccine, focusing on thermostable oral circular RNA-based vaccines.
Esperovax received a $1 million award to further develop a yeast-based oral COVID-19 RNA vaccine candidate as part of the BLUE KNIGHT™ QuickFire Challenge, supporting critical studies on vaccine safety and immunoprotection.
Dr. Robin Robinson, a renowned leader in vaccines and biothreats, was appointed as President and CEO to lead the company into further development of its oral RNA vaccine and therapeutics.
Esperovax partnered with Ginkgo Bioworks to develop circular RNAs for therapeutic applications, initially targeting colorectal cancer.
Esperovax signed an agreement with the University of Michigan to produce vaccines and therapeutics using a yeast-based manufacturing method, enabling continuous production and higher yields.
Co-Authored piece examines Aques Two-Phase System aimed at speeding vaccination production, quick deployment for today’s healthcare needs.
Esperovax was awarded a subcontract valued at $1.5 million for the pre-clinical development of an oral H5N1 influenza RNA vaccine, focusing on thermostable oral circular RNA-based vaccines.
Esperovax received a $1 million award to further develop a yeast-based oral COVID-19 RNA vaccine candidate as part of the BLUE KNIGHT™ QuickFire Challenge, supporting critical studies on vaccine safety and immunoprotection.
Dr. Robin Robinson, a renowned leader in vaccines and biothreats, was appointed as President and CEO to lead the company into further development of its oral RNA vaccine and therapeutics.
Esperovax partnered with Ginkgo Bioworks to develop circular RNAs for therapeutic applications, initially targeting colorectal cancer.
Esperovax signed an agreement with the University of Michigan to produce vaccines and therapeutics using a yeast-based manufacturing method, enabling continuous production and higher yields.
Co-Authored piece examines Aques Two-Phase System aimed at speeding vaccination production, quick deployment for today’s healthcare needs.